No insider purchase over the last 90 days. The latest, by 김태군, was filed 10 Apr 2026.
Remed Co.,Ltd.: what insiders have been doing
Every trade that managers of Remed Co.,Ltd. disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. In the past year (1 November 2025 to 1 November 2026), 23 filings came from 6 insiders.
No insider sold shares on the market over the period. Instead, the filings list 10 purchases totalling €136k, made by 5 insiders. The totals do not cover 7 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €125k, bought by 이근용 and made public on 27 March 2026 (0.24% of market cap). The buyers include 3 senior executives and 1 finance chief.
In all, 2 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 10 April 2026, 213 days ago. Filings reach the DART (FSS) feed a median of 4 days after the trade. That lag is the time during which only the insider knows about the trade.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 23 filings, this issuer sits above that mark. Since 2021, the database holds 11 purchases and 2 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -22.8%Entry ₩2,965 · Close 30 Oct 2026 ₩2,290
- -22.8%Entry ₩2,965 · Close 30 Oct 2026 ₩2,290
- -21.4%Entry ₩2,915 · Close 30 Oct 2026 ₩2,290
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- ●Executives0DART
- ●Executives0DART
- 0KRXDART:20260528000700
- 0KRXDART:20260504000394
- 0KRXDART:20260429000753
- 3,300 shares0.011% mcap4.4% of flowKRXDART:20260410002224Canonical exit: 8 Jul 2026 (T+90)
- 3,300 shares@ ₩2,880.000.011% mcap100.0% of flowShareKRXDART:20260410002312Canonical exit: 8 Jul 2026 (T+90)
- 0KRXDART:20260403003000
- 70,000 shares0.24% mcap95.6% of flowKRXDART:20260327001420Canonical exit: 21 Jun 2026 (T+90)
- 0KRXDART:20260319000235
- 0KRXDART:20260312000926
- ●Executives0DART
- 2,500 sharesShareKRXDART:20260303003108Canonical exit: 26 May 2026 (T+90)
- 3,800 sharesKRXDART:20260226006838Canonical exit: 20 May 2026 (T+90)
- 3,100 sharesShareKRXDART:20260205000435Canonical exit: 6 May 2026 (T+90)
- 1,800 sharesKRXDART:20260203000449Canonical exit: 28 Apr 2026 (T+90)
25 of 92 declarations
About Remed Co.,Ltd.
리메드 operates in the healthcare and pharmaceutical sector, listed on the XKRX market. The company focuses on developing innovative solutions to enhance healthcare.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
